Goldman Sachs initiated coverage of Adaptive Biotechnologies (ADPT) with a Buy rating and a $35.00 price target. The firm cited the company’s growth potential in immune-driven medicine and its innovative technologies.
Adaptive Biotechnologies develops immune medicine technologies, including high-throughput sequencing. Its flagship product, clonoSEQ, is an FDA-cleared assay used to detect and monitor minimal residual disease in certain cancers.